ABSTRACT NUMBER: ESOC2026A2331 PRECISION STROKE SECONDARY PREVENTION USING CYP2C19 GENOTYPE POINT-OF-CARE TESTING
Radim Licenik, Charlotte Murray, Mohammad Haque, Mmua Ngwako, Suleman Mohammed, Mohsen Kermani, Silvie Davis, Dipraj Limbu, Martin Huncovsky · 2026
Read ABSTRACT NUMBER: ESOC2026A2331 PRECISION STROKE SECONDARY PREVENTION USING CYP2C19 GENOTYPE POINT-OF-CARE TESTING by Radim Licenik, Charlotte Murray, Mohammad Haque, Mmua Ngwako, Suleman Mohammed, Mohsen Kermani, Silvie Davis, Dipraj Limbu, Martin Huncovsky (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13144915.txt.
Description
Radim Licenik and co-authors report bedside genetic testing after stroke in a 2026 conference abstract. The standard preventive drug clopidogrel fails in over a quarter of people because a liver enzyme variant, in the CYP2C19 gene, cannot activate it properly, leaving them exposed to another stroke.
A point-of-care test checked the six commonest variants in selected patients: the young, those with repeat events, and those who had clot-removal treatment. Results sorted patients from poor to ultra-rapid metabolizers, and a multidisciplinary team adjusted each prescription. The abstract presents the rollout, run over most of a year, as precision prevention in action.
Catalog record
| CREATOR | Radim Licenik, Charlotte Murray, Mohammad Haque, Mmua Ngwako, Suleman Mohammed, Mohsen Kermani, Silvie Davis, Dipraj Limbu, Martin Huncovsky |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |